OSIS

OSI Systems, Inc. (OSIS) - Q2 Fiscal 2026 Summary

Business Context and Reporting Period

This summary covers the unaudited quarterly report (Form 10-Q) for OSI Systems, Inc. for the period ended December 31, 2025 (Q2 Fiscal 2026). OSI is a vertically integrated designer and manufacturer of specialized electronic systems and components for homeland security, healthcare, defense, and aerospace markets. The company operates through three primary divisions: Security, Optoelectronics and Manufacturing, and Healthcare.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total net revenues increased 10.5% year-over-year (Q2) and 11.1% year-over-year (YTD). The Security division drove growth with a 15.4% increase in Q2, fueled by aviation screening systems and RF products. The Optoelectronics division also grew 9.2% in Q2. Conversely, the Healthcare division declined 18.7% in Q2 due to lower patient monitoring sales.
• Margin Compression: Gross margins decreased from 35.0% to 32.7% in Q2 and from 35.2% to 32.4% YTD. Management attributed this to a less favorable product mix in the current period compared to the prior year.
• Restructuring Charges: Impairment, restructuring, and other charges increased significantly to $2.9 million in Q2 (vs. $0.2 million prior year) and $5.6 million YTD (vs. $1.4 million prior year). These included asset impairments, employee terminations, and business unit modifications in the Healthcare and Security divisions.
• Debt Structure: In November 2025, the company issued $575.0 million in 0.50% Convertible Senior Notes due 2031. In July 2025, the revolving credit facility was amended to increase the limit to $725 million and extend maturity to 2030.

Outlook, Risks, and Unusual Items

• Unusual Items: Interest and other expense increased due to a $4.4 million charge in Q2 for prior service cost amortization related to a pension plan amendment for the former CEO. Additionally, the company recognized discrete tax benefits totaling $1.7 million YTD related to equity-based compensation and prior year estimate changes.
• Convertible Notes: The 2.25% Convertible Senior Notes due 2029 became eligible for conversion by holders starting January 2, 2026, as the stock price exceeded 130% of the conversion price. The company intends to use its revolving credit facility to settle conversions if they occur.
• Risks: Key risks include global economic uncertainty, trade tariffs, supply chain disruptions, and the impact of geopolitical conflicts (Russia-Ukraine, Middle East). The company notes that currency exchange rates positively impacted sales by 0.6% YTD due to a weaker U.S. dollar.
• Capital Allocation: The company repurchased 546,945 shares for approximately $146.1 million in November 2025 in connection with the 2031 Notes issuance. Approximately $611.4 million remains available under the revolving credit facility.

Investor Verification Checklist

• Convertible Note Conversion Risk: Verify the potential dilution or cash outflow if holders of the 2029 Notes exercise conversion rights in Q3 2026.
• Healthcare Division Trend: Monitor the Healthcare division's revenue trajectory, which has declined for two consecutive quarters, to assess if this is a temporary dip or a structural shift.
• Margin Recovery: Assess whether the company can improve gross margins in the second half of the fiscal year given the current mix of lower-margin services and higher-cost components.
• Debt Covenants: Confirm continued compliance with financial covenants under the amended credit facility and indentures, particularly given the increased debt load from the 2031 Notes.
• Restructuring Execution: Track the realization of cost savings from the $5.6 million in restructuring charges incurred YTD.